Amgen (AMGN) Expected to Release Quarterly Earnings on Tuesday

Amgen (NASDAQ:AMGN) is expected to release its Q3 2026 results after the market closes on Tuesday, November 3rd. Analysts expect Amgen to post earnings of $5.79 per share and revenue of $10.08 billion for the quarter. Amgen has set its FY 2026 guidance at 22.300-23.500 EPS. Interested persons can find conference call details on the company’s upcoming Q3 2026 earnings report for the latest details on the call scheduled for Tuesday, November 3, 2026 at 4:30 PM ET.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, August 4th. The medical research company reported $6.29 earnings per share for the quarter, topping analysts’ consensus estimates of $5.62 by $0.67. Amgen had a net margin of 22.95% and a return on equity of 124.14%. The company had revenue of $10.05 billion during the quarter, compared to the consensus estimate of $9.43 billion. During the same quarter in the prior year, the firm posted $6.02 EPS. The firm’s quarterly revenue was up 9.5% on a year-over-year basis. On average, analysts expect Amgen to post $22.96 EPS for the current fiscal year and $24.60 EPS for the next fiscal year.

Amgen Trading Up 1.2%

Shares of AMGN opened at $444.63 on Tuesday. The company has a debt-to-equity ratio of 4.44, a quick ratio of 1.13 and a current ratio of 1.37. Amgen has a 52-week low of $288.00 and a 52-week high of $450.98. The firm has a market cap of $240.38 billion, a price-to-earnings ratio of 27.63, a PEG ratio of 3.21 and a beta of 0.41. The business’s fifty day moving average is $417.26 and its 200-day moving average is $371.70.

Amgen Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, September 11th. Investors of record on Friday, August 21st were given a dividend of $2.52 per share. The ex-dividend date was Friday, August 21st. This represents a $10.08 dividend on an annualized basis and a yield of 2.3%. Amgen’s payout ratio is currently 62.65%.

Key Amgen News

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen and AstraZeneca reported that Imdelltra combined with Imfinzi reduced the risk of death by 58% in a Phase 3 study of patients with extensive-stage small-cell lung cancer. Median overall survival reached 21.1 months, strengthening the commercial and pipeline outlook for Imdelltra. Amgen, AstraZeneca Drug Combo Shows Promising Survival Results in Tough-To-Treat Lung Cancer
• Positive Sentiment: The strong lung-cancer results received significant attention at ESMO 2026, with coverage describing Amgen’s data as “unprecedented.” The readout could support future regulatory and market-share expectations for Imdelltra. ESMO ‘26: A cancer vaccine debate, Roche’s KRAS progress and Amgen’s ‘unprecedented’ data
• Positive Sentiment: Oppenheimer reiterated its Outperform rating, indicating continued confidence in Amgen’s growth prospects and clinical pipeline. Oppenheimer Reiterates Outperform Rating on Amgen

Wall Street Analysts Forecast Growth

Several equities analysts have issued reports on AMGN shares. Barclays upped their price target on shares of Amgen from $380.00 to $400.00 and gave the company an “equal weight” rating in a research report on Wednesday, October 21st. Cantor Fitzgerald lifted their price objective on Amgen from $400.00 to $440.00 and gave the stock a “neutral” rating in a research note on Monday, October 5th. Canaccord Genuity Group lifted their price objective on Amgen from $366.00 to $384.00 and gave the stock a “hold” rating in a research note on Wednesday, August 5th. Sanford C. Bernstein upped their price objective on shares of Amgen from $335.00 to $345.00 and gave the company a “market perform” rating in a research note on Thursday, August 6th. Finally, HSBC lowered shares of Amgen from a “buy” rating to a “hold” rating and reduced their price objective for the company from $445.00 to $425.00 in a research note on Thursday, September 10th. One analyst has rated the stock with a Strong Buy rating, ten have given a Buy rating, sixteen have issued a Hold rating and three have assigned a Sell rating to the stock. Based on data from MarketBeat, Amgen currently has an average rating of “Hold” and a consensus target price of $389.71.

Insiders Place Their Bets

In other news, SVP Rachna Khosla sold 1,252 shares of the stock in a transaction that occurred on Thursday, August 13th. The stock was sold at an average price of $416.43, for a total value of $521,370.36. Following the completion of the sale, the senior vice president directly owned 6,404 shares of the company’s stock, valued at $2,666,817.72. This represents a 16.35% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, SVP Nancy A. Grygiel sold 2,970 shares of the stock in a transaction that occurred on Thursday, August 6th. The stock was sold at an average price of $402.16, for a total value of $1,194,415.20. Following the completion of the sale, the senior vice president directly owned 7,340 shares of the company’s stock, valued at approximately $2,951,854.40. This trade represents a 28.81% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders have sold a total of 6,222 shares of company stock valued at $2,540,926 in the last 90 days. 0.85% of the stock is currently owned by company insiders.

About Amgen

Amgen Inc is a biotechnology company that discovers, develops, manufactures and delivers medicines for serious illnesses. Its research focuses on areas including oncology, cardiovascular disease, inflammation, bone health, nephrology and neuroscience.

The company’s products include biologic and specialty medicines such as Enbrel for inflammatory diseases, Prolia and Evenity for osteoporosis, Xgeva for skeletal-related complications, Repatha for cardiovascular risk reduction, Otezla for inflammatory conditions, Tezspire for severe asthma, Blincyto for certain blood cancers, and Lumakras for specific cancers.

Founded in 1980, Amgen is headquartered in Thousand Oaks, California.